The Modified Response Evaluation Criteria in Solid Tumors (RECIST) Yield a More Accurate Prognoses Than the RECIST 1.1 in Hepatocellular Carcinoma Treated with Transarterial Radioembolization
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: The Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and modified RECIST (mRECIST) criteria have been used to assess treatment responses for hepatocellular carcinoma (HCC) patients. We investigated which criteria provides better survival predictions in HCC patients treated with transarterial radioembolization (TARE). Methods: In total, 102 patients with unresectable intrahepatic HCC, who were treated with TARE between 2012 and 2017, were reviewed retrospectively. The treatment response after TARE was evaluated at 1, 3, and 6 months by the mRECIST and RECIST 1.1. Responders were defined as patients with complete or partial responses by each criterion. Results: The median age of 83 men and 19 women was 64.3 years. The median alpha-fetoprotein and des-gamma-carboxy prothrombin levels were 37.1 ng/mL and 1,780.0 mAU/mL, respectively. The median maximal tumor size was 8.3 cm, and multiple tumors were observed in 36 patients (35.3%). During the follow-up period (median, 20.7 months), 21 patients (20.6%) died, with a mean survival time of 55.5 months. The cumulative survival rate was 96.1% at 6 months and 89.3% at 12 months. Responders, defined by the mRECIST at 1, 3, and 6 months after TARE, showed better survival outcomes than nonresponders (hazard ratio [HR]=5.736, p=0.008 at 1 month; HR=3.145, p=0.022 at 3 months, and HR=2.887, p=0.061 at 6 months). The survival rates of responders and nonresponders defined by the RECIST 1.1 were similar (all p>0.05). Conclusions: Response evaluations that use the mRECIST provide more accurate prognoses than those that use the RECIST 1.1 in HCC patients treated with TARE.
Abstract
Background/Aims: The Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and modified RECIST (mRECIST) criteria have been used to assess treatment responses for hepatocellular carcinoma (HCC) patients. We investigated which criteria provides better survival predictions in HCC patients treated with transarterial radioembolization (TARE). Methods: In total, 102 patients with unresectable intrahepatic HCC, who were treated with TARE between 2012 and 2017, were reviewed retrospectively. The treatment response after TARE was evaluated at 1, 3, and 6 months by the mRECIST and RECIST 1.1. Responders were defined as patients with complete or partial responses by each criterion. Results: The median age of 83 men and 19 women was 64.3 years. The median alpha-fetoprotein and des-gamma-carboxy prothrombin levels were 37.1 ng/mL and 1,780.0 mAU/mL, respectively. The median maximal tumor size was 8.3 cm, and multiple tumors were observed in 36 patients (35.3%). During the follow-up period (median, 20.7 months), 21 patients (20.6%) died, with a mean survival time of 55.5 months. The cumulative survival rate was 96.1% at 6 months and 89.3% at 12 months. Responders, defined by the mRECIST at 1, 3, and 6 months after TARE, showed better survival outcomes than nonresponders (hazard ratio [HR]=5.736, p=0.008 at 1 month; HR=3.145, p=0.022 at 3 months, and HR=2.887, p=0.061 at 6 months). The survival rates of responders and nonresponders defined by the RECIST 1.1 were similar (all p>0.05). Conclusions: Response evaluations that use the mRECIST provide more accurate prognoses than those that use the RECIST 1.1 in HCC patients treated with TARE.
참고문헌 (37)
- McGlynn KA, "Global epidemiology of hepatocellular carcinoma : an emphasis on demographic and regional variability", Clin Liver Dis, 19, pp.223~238 (2015)
- Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC, "2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma", Gut and Liver, 13(3), pp.227~299 (2019), 거트앤리버 소화기연관학회협의회[DOI]
- Sotiropoulos GC, "Resectability of hepatocellular carcinoma : evaluation of 333 consecutive cases at a single hepatobiliary specialty center and systematic review of the literature", Hepatogastroenterology, 53, pp.322~329 (2006)
- 김준영, "Transarterial chemoembolization versus resection for the intermediate stage hepatocellular carcinoma", Clinical and Molecular Hepatology, 22(2), pp.250~258 (2016), 대한간학회
- Sangro B, "Transarterial chemoembolization and radioembolization", Semin Liver Dis, 34, pp.435~443 (2014)
- Salem R, "Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres : a comprehensive report of long-term outcomes", Gastroenterology, 138, pp.52~64 (2010)
- Hilgard P, "Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma : European experience on safety and long-term survival", Hepatology, 52, pp.1741~1749 (2010)
- Kulik LM, "Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis", Hepatology, 47, pp.71~81 (2008)
- Kim HC, "Radioembolization for the treatment of hepatocellular carcinoma", Clin Mol Hepatol, 23, pp.109~114 (2017)
- Mazzaferro V, "Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma : a phase 2 study", Hepatology, 57, pp.1826~1837 (2013)
- Sangro B, "Survival after yttrium-90resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages : a European evaluation", Hepatology, 54, pp.868~878 (2011)
- Gabr A, "Outcomes of surgical resection after radioembolization for hepatocellular carcinoma", J Vasc Interv Radiol, 29, pp.1502~1510 (2018)
- Song JE, "Transarterial radioembolization versus concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma : a propensity score matching analysis", Int J Radiat Oncol Biol Phys, 99, pp.396~406 (2017)
- Miller AB, "Reporting results of cancer treatment", Cancer, 47, pp.207~214 (1981)
- Therasse P, "New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada", J Natl Cancer Inst, 92, pp.205~216 (2000)
- Lencioni R, "Modified RECIST(mRECIST)assessment for hepatocellular carcinoma", Semin Liver Dis, 30, pp.52~60 (2010)
- Kim SU, "Clinical application of liver stiffness measurement using transient elastography : a surgical perspective", Digestion, 88, pp.258~265 (2013)
- Kim MN, "Evolution from WHO to EASL and mRECIST for hepatocellular carcinoma : considerations for tumor response assessment", Expert Rev Gastroenterol Hepatol, 9, pp.335~348 (2015)
- Llovet JM, "Design and endpoints of clinical trials in hepatocellular carcinoma", J Natl Cancer Inst, 100, pp.698~711 (2008)
- Jeon MY, "Reproducibility of European Association for the Study of the Liver criteria and modified Response Evaluation Criteria in Solid Tumors in patients treated with sorafenib", Liver Int, 38, pp.1655~1663 (2018)
- Kim BK, "Number of target lesions for EASL and modified RECIST to predict survivals in hepatocellular carcinoma treated with chemoembolization", Clin Cancer Res, 19, pp.1503~1511 (2013)
- Kim BK, "Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation", Eur J Cancer, 49, pp.826~834 (2013)
- Kim BK, "Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma", J Hepatol, 62, pp.1304~1310 (2015)
- Weng Z, "Choi criteria are superior in evaluating tumor response in patients treated with transarterial radioembolization for hepatocellular carcinoma", Oncol Lett, 6, pp.1707~1712 (2013)
- Riaz A, "Radioembolization for hepatocellular carcinoma : statistical confirmation of improved survival in responders by landmark analyses", Hepatology, 67, pp.873~883 (2018)
- Bester L, "Imaging characteristics following 90yttrium microsphere treatment for unresectable liver cancer", J Med Imaging Radiat Oncol, 55, pp.111~118 (2011)
- Semaan S, "Imaging of hepatocellular carcinoma response after(90)y radioembolization", AJR Am J Roentgenol, 209, pp.W263~W276 (2017)
- Tae-Hyung Kim, "Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma: 2018 update", Clinical and Molecular Hepatology, 25(3), pp.245~263 (2019), 대한간학회
- 한국 간 암 스터디그룹, "2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma", Gut and Liver, 9(3), pp.267~317 (2015), 거트앤리버 소화기연관학회협의회
- Mitchell DG, "LI-RADS(Liver Imaging Reporting and Data System) : summary, discussion, and consensus of the LI-RADS Management Working Group and future directions", Hepatology, 61, pp.1056~1065 (2015)
- Lewandowski RJ, "Radioembolization with 90Y microspheres : angiographic and technical considerations", Cardiovasc Intervent Radiol, 30, pp.571~592 (2007)
- Eisenhauer EA, "New response evaluation criteria in solid tumours : revised RECIST guideline(version 1. 1)", Eur J Cancer, 45, pp.228~247 (2009)
- Vouche M, "Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI : imaging analysis from a prospective randomized trial of Y90 ± sorafenib", Hepatology, 58, pp.1655~1666 (2013)
- Kim JW, "Radiological-pathological correlation study of hepatocellular carcinoma undergoing local chemoradiotherapy and surgery", J Gastroenterol Hepatol, 31, pp.1619~1627 (2016)
- Bibault JE, "Stereotactic body radiation therapy for hepatocellular carcinoma : prognostic factors of local control, overall survival, and toxicity", PLoS One, 8, pp.e77472~ (2013)
- Khor AY, "Survival and pattern of tumor progression with yttrium-90 microsphere radioembolization in predominantly hepatitis B Asian patients with hepatocellular carcinoma", Hepatol Int, 8, pp.395~404 (2014)
- Sato Y, "Tumor response evaluation criteria for HCC(hepatocellular carcinoma)treated using TACE(transcatheter arterial chemoembolization) : RECIST(Response Evaluation Criteria in Solid Tumors)version 1. 1 and mRECIST(modified RECIST) : JIVROSG-0602", Ups J Med Sci, 118, pp.16~22 (2013)